MedTrace Logo

TACE With Thermosensitive Nanogel Versus Embosphere for HCC

NCT06593964 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 188

Last updated 2024-09-19

No results posted yet for this study

Summary

To verify the safety and efficacy of TACE withThermosensitive Nanogel Embolic Agent for HCC.

Conditions

Interventions

DEVICE

Thermosensitive Nanogel Embolic Agent

Thermosensitive Nanogel Embolic Agent

Sponsors & Collaborators

  • Zhongda Hospital

    lead OTHER

Principal Investigators

  • Gao-Jun Teng, M.D. · Zhongda Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-10
Primary Completion
2026-04-30
Completion
2026-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06593964 on ClinicalTrials.gov